Drugs / bicyclol
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT02944552 | Aug 2017 → Jun 2019 | drug-induced liver injury | Drug Induced Liver Disease Study Group | Completed | Met primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT05063500 | Dec 2021 → May 2023 | drug-induced liver injury | Drug Induced Liver Disease Study Group | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05711459 | May 2022 → May 2023 | drug-induced liver injury | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bicyclol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05711459 ↗ |
| Known as | Bicyclol tablets | “Take Bicyclol tablets for the treatment of liver injury.” NCT05711459 ↗ |
| Modality | Small molecule | — CHEMBL482035 ↗ |
| Route | Oral | “bicyclol tablet 25mg orally” NCT02944552 ↗ |